Payment overview · 2025
General Payments
$1,514.25
68 reported records · 17 companies
Healthcare provider profile · identity verified
Sureshkumar Muttath, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · RIVERDALE, MD · NPI 1275599458
Verified facts
What the public records show
CMS Open Payments records show Sureshkumar Muttath, M.D. received $1,514.25 in general payments during 2025 across 68 reported records.
Corcept Therapeutics accounted for 25.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $383.17 | 25.3% | 13 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $176.94 | 11.7% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $140.71 | 9.3% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $129.98 | 8.6% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $111.23 | 7.3% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $106.40 | 7.0% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $100.16 | 6.6% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $86.41 | 5.7% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $81.48 | 5.4% | 4 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $33.37 | 2.2% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $31.03 | 2.0% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $28.50 | 1.9% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $27.52 | 1.8% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $23.61 | 1.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.14 | 1.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.92 | 1.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.68 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,514.25 | 68 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $383.17 | 13 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $176.94 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $114.20 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $94.14 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $86.41 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $81.48 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $80.66 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $74.09 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $74.09 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $68.44 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $61.09 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $61.09 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $61.09 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $46.57 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $45.31 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $45.31 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $37.14 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $35.92 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $33.37 | 2 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $33.37 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $31.03 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $31.03 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $28.50 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $27.52 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $15.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 44 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 87 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 69 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
83 | 36 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
87 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
69 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
87 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
44 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 291 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 248 | 108 |
| Pantoprazole Sodium | Pantoprazole Sodium | 214 | 86 |
| Losartan Potassium | Losartan Potassium | 206 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 195 | 79 |
| Gabapentin | Gabapentin | 179 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 178 | 65 |
| Metformin Hcl | Metformin Hcl | 170 | 65 |
| Famotidine | Famotidine | 149 | 61 |
| Potassium Chloride | Potassium Chloride | 124 | 38 |
| Furosemide | Furosemide | 117 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 113 | 45 |
| Oxycodone Hcl | Oxycodone Hcl | 111 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 105 | 43 |
| Alprazolam | Alprazolam | 87 | 20 |
| Jardiance | Empagliflozin | 87 | 32 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 85 | 11 |
| Ozempic | Semaglutide | 84 | 22 |
| Farxiga | Dapagliflozin Propanediol | 83 | 36 |
| Lorazepam | Lorazepam | 82 | 18 |
| Diclofenac Sodium Er | Diclofenac Sodium | 79 | 31 |
| Morphine Sulfate Er | Morphine Sulfate | 76 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 36 |
| Finasteride | Finasteride | 72 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 69 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 17 |
| Carvedilol | Carvedilol | 67 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 27 |
| Tramadol Hcl | Tramadol Hcl | 60 | 17 |
| Pregabalin | Pregabalin | 59 | 16 |
| Lisinopril | Lisinopril | 58 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 57 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 25 |
| Omeprazole | Omeprazole | 56 | 11 |
| Prednisone | Prednisone | 56 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 30 |
| Glipizide | Glipizide | 51 | 22 |
| Allopurinol | Allopurinol | 49 | 24 |
| Azithromycin | Azithromycin | 49 | 40 |
| Mirtazapine | Mirtazapine | 47 | 20 |
| Xarelto | Rivaroxaban | 47 | 17 |
| Diazepam | Diazepam | 46 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 46 | 22 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 46 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 19 |
| Trazodone Hcl | Trazodone Hcl | 45 | 12 |
| Eliquis | Apixaban | 44 | 24 |
| Linzess | Linaclotide | 43 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 13 |
| Montelukast Sodium | Montelukast Sodium | 40 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Atenolol | Atenolol | 38 | 12 |
| Fenofibrate | Fenofibrate | 38 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 34 | suppressed |
| Entresto | Sacubitril/Valsartan | 33 | 13 |
| Fentanyl | Fentanyl | 33 | suppressed |
| Kerendia | Finerenone | 33 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 33 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 32 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 14 |
| Spironolactone | Spironolactone | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Simvastatin | Simvastatin | 26 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 24 | 21 |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 17 |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 21 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 20 | 11 |
| Fluconazole | Fluconazole | 20 | 15 |
| Glipizide Er | Glipizide | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Klor-Con M10 | Potassium Chloride | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 14 |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Methadone Hcl | Methadone Hcl | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | 12 |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,514.25 · 68 records | Corcept Therapeutics | ABRYSVO, AIRSUPRA, BREZTRI, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, ENFLONSIA, EVENITY, FUROSCIX, Fluad, Flucelvax, GARDASIL 9, ImmunoCAP, JARDIANCE, Korlym, MOUNJARO, NURTEC ODT, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, SKYCLARYS, TRELEGY ELLIPTA, UBRELVY, VAXELIS, VOQUEZNA, Wegovy, YUPELRI, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error